Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151579 · ClinicalTrials.gov registry record · Phase 4
Effect of Nebulized Bronchodilators on Heart Rate
A Phase 4 study of Sepsis and COPD, sponsored by Fahim Khorfan, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01151579: Completed Phase 4 study of Sepsis and COPD, sponsored by Fahim Khorfan, MD.
NCT01151579 is a Phase 4 study of Sepsis and COPD that has completed, run by Fahim Khorfan, MD. The registered enrollment target is 89 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01151579, a Phase 4 study of Sepsis and COPD, has completed, sponsored by Fahim Khorfan, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
Primary Outcome
Average difference in Heart rate between pre and post breathing treatments
Interventions
- DRUG Albuterol
- DRUG Levalbuterol
Study Locations (1)
Michigan
- Genesys Regional Medical Center - Grand Blanc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
What the finished NCT01151579 record still lists
NCT01151579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Albuterol is the first listed.
NCT01151579 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01151579 about?
NCT01151579 is a clinical study titled "Effect of Nebulized Bronchodilators on Heart Rate". The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
What is the current status of trial NCT01151579?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2008-12. Estimated completion is 2009-11.
What conditions does trial NCT01151579 study?
This clinical trial studies the following conditions: Sepsis, COPD, Shock.
What interventions are being tested in trial NCT01151579?
The interventions under investigation include: Albuterol (DRUG), Levalbuterol (DRUG).
Who is sponsoring clinical trial NCT01151579?
This trial is sponsored by Fahim Khorfan, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01151579 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01151579's enrollment target sits among peer trials
89 60th of 90 higher than 31 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
The PASTDUe Nutrition Ecosystem Project (PASTDUe)
ACTIVE NOT RECRUITING · Phase 4
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia